Google Ad

AIM ImmunoTech (NYSEAMERICAN:AIM)on Monday announced testing its SARS vaccine Ampligen as a potential treatment for the new coronavirus (SARS-CoV-2).The stock $AIM leapt over 300% on the news

Coronavirus Spores

AIM ImmunoTech on a news rlease said will be testing its Ampligen as a potential treatment for the new coronavirus (SARS-CoV-2). The tests will be carried out in Japan and overseen by the World Health Organization’s Hideki Hasegawa, MD, PhD.

AIM ImmunoTech claims that Ampligen may do well in treating coronavirus due to its previous effectiveness with the original SARS coronavirus (SARS-CoV-1). In testing with mice, this saw all treated mice survive while all untreated ones died.

Ampligen’s results for treating SARS-CoV-1 matter because due to the similar makeup of the two viruses. The new coronavirus has regulatory RNA sequences that are almost identical to the previous version of the virus. Thomas Equels, Chief Executive Officer of AIM ImmunoTech, said the following about the AIM stock news. “Because SARS-CoV-2 shares many critical similarities with SARS-CoV-1,

Ampligen may have an important role to play in developing a protective early-onset therapy for this new highly pathogenic coronavirus in humans, where currently there is no known effective therapy. We are proud to work with Japan’s universally esteemed NIID in the battle to curb this emerging potential pandemic.”

Source; AIM ImmunoTech

From The TradersCommunity News Desk

Log in to comment
Discuss this article in the forums (1 replies).